Status:
UNKNOWN
Hemodynamic Changes in Acute Ischaemic Stroke Patients
Lead Sponsor:
Assiut University
Conditions:
Acute Stroke
Eligibility:
All Genders
18-80 years
Brief Summary
1. To assess Hemodynamic changes in rtPA receiving Acute Ischaemic Stroke patients. 2. To assess the efficacy of rtPA in treatment of Acute Ischaemic Stroke patients. 3. To correlate TCD findings (pos...
Detailed Description
* Stroke is a major healthcare issue worldwide representing the third most common cause of death in the United Kingdom. Approximately 50% of cerebrovascular events were in those aged under 75 years de...
Eligibility Criteria
Inclusion
- age \> 18, both sexes, acute ischemic stroke within 4.5 hours, NIHSS (5-25)
Exclusion
- Significant head trauma or prior stroke in the previous 3 months
- Symptoms suggest subarachnoid hemorrhage
- Arterial puncture at a noncompressible site in previous 7 days
- History of previous intracranial hemorrhage
- Intracranial neoplasm, AVM, or an aneurysm
- Recent intracranial or intraspinal surgery
- Elevated blood pressure (systolic greater than 185 mmHg or diastolic greater than 110 mmHg)
- Active internal bleeding
- Acute bleeding diathesis, including but not limited to
- Platelet count less than 100 000/mm\^3
- Heparin received within 48 hours resulting in abnormally elevated aPTT above the upper limit of normal
- Current use of anticoagulant with INR greater than 1.7 or PT greater than 15 seconds
- Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive laboratory tests (e.g., aPTT, INR, platelet count, ECT, TT, or appropriate factor Xa activity assays)
- Blood glucose concentration less than 50 mg/dL (2.7 mmol/L)
- CT demonstrates multilobar infarction (hypodensity greater than a one-third cerebral hemisphere) Relative Exclusion Criteria
- Recent experience suggests that under some circumstances, with careful consideration and weighing of risk to benefit, patients may receive fibrinolytic therapy despite 1 or more relative contraindications. Consider the risk to the benefit of intravenous rtPA administration carefully if any of these relative contraindications are present:
- Only minor or quickly improving stroke symptoms (clearing automatically)
- Pregnancy
- Seizure at the onset with postictal residual neurological impairments
- Major surgery or serious trauma within prior 14 days
- Recent GI or urinary tract hemorrhage (within previous 21 days)
Key Trial Info
Start Date :
January 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05195983
Start Date
January 10 2022
End Date
March 1 2025
Last Update
January 19 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.